The impaired reactivity may play a role in organ injury, the authors suggested, among patients who have immune-mediated thrombotic thrombocytopenic purpura (iTTP). People with immune-mediated ...
A panel of experts suggests adding caplacizumab to the historic treatment of plasma exchange and immunosuppression could lead to significant improvement in outcomes for patients with immune-mediated ...
A recombinant form of human ADAMTS13 approved for a different condition helped to save the life of a young mother with immune thrombotic thrombocytopenic purpura. A team led by investigators from ...
Supported by a grant (1R01HL166246, to Dr. Bendapudi) from the National Institutes of Health and by the Luick Family Fund of the Department of Pathology at Massachusetts General Hospital. Disclosure ...
A team led by investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, used a new drug to save the life of a patient with immune thrombotic ...
Immune thrombotic thrombocytopenic purpura, a rare blood clotting disorder, results from an autoimmune attack against an enzyme called ADAMTS13 A recombinant form of human ADAMTS13 approved for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results